The Ireland-based company, which this year announced acapital raise of $315 million, is focused exclusively on research around the psychoactive molecule 5-MeO-DMT to treat depression, a condition that affects many millions of people around the world. Currently, an estimated 50 percent of patients receiving therapy for TRD do not respond to approved depression medications.
The lack of effective treatments for TRD has created a market for companies like GH Research seeking to develop such therapies, potentially changing the way TRD is treated today. So far, GH Research is on track to validate claims that their proprietary GH001 5-MeO-DMT formula is safe and could provide relief from TRD with no serious adverse events for patients.
Completing two Phase 1 healthy-volunteer clinical trials and a Phase 1/2 clinical trial in patients with TRD, studies have so far revealed that 87.5% of patients were brought into an ultra-rapid remission after an individualized single-day dosing regimen using GH Research’s inhalable 5-MeO-DMT product.
